# Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder

> **NCT02672111** · PHASE3 · COMPLETED · sponsor: **Braeburn Pharmaceuticals** · enrollment: 228 (actual)

## Conditions studied

- Opioid Use Disorder

## Interventions

- **DRUG:** CAM2038 q1w or q4w exposure to SL BPN/NX
- **DRUG:** CAM2038 q1w or q4w new to BPN treatment

## Key facts

- **NCT ID:** NCT02672111
- **Lead sponsor:** Braeburn Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2020-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02672111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02672111, "Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02672111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*